Literature DB >> 2283251

Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection.

M Van Wagoner1, M O'Toole, S C Quay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2283251     DOI： 10.1097/00004424-199009001-00018

Source DB:  PubMed          Journal:  Invest Radiol        ISSN： 0020-9996            Impact factor:   6.016


× No keyword cloud information.
  3 in total

1.  Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective.

Authors:  V Aslanian; H Lemaignen; P Bunouf; M G Svaland; A Borseth; B Lundby
Journal:  Neuroradiology       Date:  1996-08       Impact factor: 2.804

2.  A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system.

Authors:  J Valk; P R Algra; C J Hazenberg; W B Slooff; M G Svaland
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

3.  Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA.

Authors:  P Akeson; E Jonsson; I Haugen; S Holtås
Journal:  Neuroradiology       Date:  1995-04       Impact factor: 2.804
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.